Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000598 | 0.95 | FDFT1 (0.83) | FDFT1 | |
| SCHEMBL13893088 | 0.95 | FDFT1 (0.83) | FDFT1 | |
| SCHEMBL8560265 | 0.93 | FDFT1 (0.72) | FDFT1 | |
| SCHEMBL8560271 | 0.93 | FDFT1 (0.72) | FDFT1 | |
| SCHEMBL8669708 | 0.93 | FDFT1 (0.72) | FDFT1 | |
| SCHEMBL4684200 | 0.91 | FDFT1 (0.89) | FDFT1 | |
| SCHEMBL4682802 | 0.91 | FDFT1 (0.78) | FDFT1 | |
| SCHEMBL4937399 | 0.89 | FDFT1 (0.78) | FDFT1 | |
| SCHEMBL14539323 | 0.88 | FDFT1 (0.73) | FDFT1 | |
| SCHEMBL13743177 | 0.86 | FDFT1 (0.62) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097928-B1 | 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-05-24 | — | — | US | disclosed |
| US-20040072819-A1 | Benzoxazepine compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-04-15 | — | — | US | disclosed |
| US-6613761-B1 | (3R,5S)-N- methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl) -1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4, 1-benzoxazepine-3-acetamide, used as antilipemic agents and enzyme inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| EP-0862562-B1 | BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1097928-A1 | 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics | Takeda Chemical Industries, Ltd. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-6110909-A | SQUALENE SYNTHETASE INHIBITING ANTILIPEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0862562-A1 | BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997010224-A1 | BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | NR1H2, APOB, CETP | FDFT1 1208/4885 |
| US-20040072819-A1 | Benzoxazepine compounds, their production and use | CES1, CETP, CYP46A1 | FDFT1 709/4885 |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | CETP, PCSK9, LPL | FDFT1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.